Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates.
Haase
Manfred
M
D002986:Clinical Trials as Topic / Q000941:ethics / Q000592:standards; D005164:Factor IX / Q000592:standards / Q000627:therapeutic use* / Q000633:toxicity; D002836:Hemophilia B / Q000188:drug therapy*; D006801:Humans; D017410:Practice Guidelines as Topic; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000592:standards / Q000633:toxicity; D018570:Risk Assessment / Q000941:ethics / Q000592:standards; D016896:Treatment Outcome
D011994:Recombinant Proteins; D005164:Factor IX